AUD 50m? ALA with just 1 or maybe 2 pre-clinicals still at AUD140. In the US, hardly anything sub USD 500m / AUD 750m with similar pipelines, ph 1 data and a CD 17 CAR-T about to go clinical. Using 750m SOI for estimation, 20c would be a MC of just AUD 150m. That would still be just 15-20% of IMU's MC.
Plenty of upside and there is a good chance that CHM overtakes IMU sp-related - hopefully not in a downwards trend as seen before when both traded at about 4c for a very short time.
GLTA
CHM Price at posting:
3.0¢ Sentiment: Buy Disclosure: Held
